FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma: First tolerability and feasibility results

Angelika Bilger; Martin Immanuel Bittner; Anca L. Grosu; Nicole Wiedenmann; Philipp T. Meyer; Elke Firat; Gabriele Niedermann; Wolfgang A. Weber; Dušan Milanović

doi:10.1007/s00066-014-0693-2

FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma: First tolerability and feasibility results

Angelika Bilger
, Martin Immanuel Bittner
, Anca L. Grosu
, Nicole Wiedenmann
, Philipp T. Meyer
, Elke Firat
, Gabriele Niedermann
, Wolfgang A. Weber
, Dušan Milanović

University of Freiburg
Weill Cornell Medical College

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Background: Treatment of recurrent glioblastoma (rGBM) remains an unsolved clinical problem. Reirradiation (re-RT) can be used to treat some patients with rGBM, but as a monotherapy it has only limited efficacy. Chloroquine (CQ) is an anti-malaria and immunomodulatory drug that may inhibit autophagy and increase the radiosensitivity of GBM.

Patients and methods: Between January 2012 and August 2013, we treated five patients with histologically confirmed rGBM with re-RT and 250 mg CQ daily.

Results: Treatment was very well tolerated; no CQ-related toxicity was observed. At the first follow-up 2 months after finishing re-RT, two patients achieved partial response (PR), one patient stable disease (SD), and one patient progressive disease (PD). One patient with reirradiated surgical cavity did not show any sign of PD.

Conclusion: In this case series, we observed encouraging responses to CQ and re-RT. We plan to conduct a CQ dose escalation study combined with re-RT.

Translated title of the contribution	FET-PET-basierte Rebestrahlung und Chloroquin bei Patienten mit rezidiviertem Glioblastom: Erste Ergebnisse zu Toleranz und Durchführbarkeit
Original language	English
Pages (from-to)	957-961
Number of pages	5
Journal	Strahlentherapie und Onkologie
Volume	190
Issue number	10
DOIs	https://doi.org/10.1007/s00066-014-0693-2
State	Published - 30 Sep 2014
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Chloroquine
Glioblastoma multiforme
Radiosensitivity
Recurrence
Reirradiation

Access to Document

10.1007/s00066-014-0693-2

Cite this

@article{730d5002492747c5a73075094e554af2,

title = "FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma: First tolerability and feasibility results",

abstract = "Background: Treatment of recurrent glioblastoma (rGBM) remains an unsolved clinical problem. Reirradiation (re-RT) can be used to treat some patients with rGBM, but as a monotherapy it has only limited efficacy. Chloroquine (CQ) is an anti-malaria and immunomodulatory drug that may inhibit autophagy and increase the radiosensitivity of GBM.Patients and methods: Between January 2012 and August 2013, we treated five patients with histologically confirmed rGBM with re-RT and 250 mg CQ daily.Results: Treatment was very well tolerated; no CQ-related toxicity was observed. At the first follow-up 2 months after finishing re-RT, two patients achieved partial response (PR), one patient stable disease (SD), and one patient progressive disease (PD). One patient with reirradiated surgical cavity did not show any sign of PD.Conclusion: In this case series, we observed encouraging responses to CQ and re-RT. We plan to conduct a CQ dose escalation study combined with re-RT.",

keywords = "Chloroquine, Glioblastoma multiforme, Radiosensitivity, Recurrence, Reirradiation",

author = "Angelika Bilger and Bittner, \{Martin Immanuel\} and Grosu, \{Anca L.\} and Nicole Wiedenmann and Meyer, \{Philipp T.\} and Elke Firat and Gabriele Niedermann and Weber, \{Wolfgang A.\} and Du{\v s}an Milanovi{\'c}",

note = "Publisher Copyright: {\textcopyright} 2014, Springer-Verlag Berlin Heidelberg.",

year = "2014",

month = sep,

day = "30",

doi = "10.1007/s00066-014-0693-2",

language = "English",

volume = "190",

pages = "957--961",

journal = "Strahlentherapie und Onkologie",

issn = "0179-7158",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "10",

}

TY - JOUR

T1 - FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma

T2 - First tolerability and feasibility results

AU - Bilger, Angelika

AU - Bittner, Martin Immanuel

AU - Grosu, Anca L.

AU - Wiedenmann, Nicole

AU - Meyer, Philipp T.

AU - Firat, Elke

AU - Niedermann, Gabriele

AU - Weber, Wolfgang A.

AU - Milanović, Dušan

PY - 2014/9/30

Y1 - 2014/9/30

N2 - Background: Treatment of recurrent glioblastoma (rGBM) remains an unsolved clinical problem. Reirradiation (re-RT) can be used to treat some patients with rGBM, but as a monotherapy it has only limited efficacy. Chloroquine (CQ) is an anti-malaria and immunomodulatory drug that may inhibit autophagy and increase the radiosensitivity of GBM.Patients and methods: Between January 2012 and August 2013, we treated five patients with histologically confirmed rGBM with re-RT and 250 mg CQ daily.Results: Treatment was very well tolerated; no CQ-related toxicity was observed. At the first follow-up 2 months after finishing re-RT, two patients achieved partial response (PR), one patient stable disease (SD), and one patient progressive disease (PD). One patient with reirradiated surgical cavity did not show any sign of PD.Conclusion: In this case series, we observed encouraging responses to CQ and re-RT. We plan to conduct a CQ dose escalation study combined with re-RT.

AB - Background: Treatment of recurrent glioblastoma (rGBM) remains an unsolved clinical problem. Reirradiation (re-RT) can be used to treat some patients with rGBM, but as a monotherapy it has only limited efficacy. Chloroquine (CQ) is an anti-malaria and immunomodulatory drug that may inhibit autophagy and increase the radiosensitivity of GBM.Patients and methods: Between January 2012 and August 2013, we treated five patients with histologically confirmed rGBM with re-RT and 250 mg CQ daily.Results: Treatment was very well tolerated; no CQ-related toxicity was observed. At the first follow-up 2 months after finishing re-RT, two patients achieved partial response (PR), one patient stable disease (SD), and one patient progressive disease (PD). One patient with reirradiated surgical cavity did not show any sign of PD.Conclusion: In this case series, we observed encouraging responses to CQ and re-RT. We plan to conduct a CQ dose escalation study combined with re-RT.

KW - Chloroquine

KW - Glioblastoma multiforme

KW - Radiosensitivity

KW - Recurrence

KW - Reirradiation

UR - https://www.scopus.com/pages/publications/84919835101

U2 - 10.1007/s00066-014-0693-2

DO - 10.1007/s00066-014-0693-2

M3 - Article

C2 - 24928248

AN - SCOPUS:84919835101

SN - 0179-7158

VL - 190

SP - 957

EP - 961

JO - Strahlentherapie und Onkologie

JF - Strahlentherapie und Onkologie

IS - 10

ER -

FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma: First tolerability and feasibility results

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this